(NYSE: OGN) Organon & Co's forecast annual revenue growth rate of 1.34% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.27%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.21%.
Organon & Co's revenue in 2026 is $6,127,000,000.On average, 9 Wall Street analysts forecast OGN's revenue for 2026 to be $1,631,067,188,363, with the lowest OGN revenue forecast at $1,545,193,903,772, and the highest OGN revenue forecast at $1,710,900,455,995. On average, 9 Wall Street analysts forecast OGN's revenue for 2027 to be $1,657,328,131,663, with the lowest OGN revenue forecast at $1,541,517,371,710, and the highest OGN revenue forecast at $1,775,764,985,946.
In 2028, OGN is forecast to generate $1,672,034,259,911 in revenue, with the lowest revenue forecast at $1,534,952,135,885 and the highest revenue forecast at $1,841,417,344,196.